https://www.selleckchem.com/products/vx-561.html
79]. There were no differences in the other outcomes including assistant rated score of facial pain [(Median (IQR), 2 (2-4) placebo and 2 (2-4) xylometazoline, p=0.36], Pain VAS [Median (IQR), placebo 2 (1-2) and xylometazoline 2 (1-3), p=0.28], Trauma VAS, [Median (IQR), placebo 1 (0-2) and xylometazoline 1 (0-1), p=0.28], hemodynamic changes, or complications between the two groups. The findings of this study do not support the administration of topical nasal xylometazoline in flexible bronchoscopy. Trial registered on Clinicaltrials.g
Like
Comment
Share
